TAXYNERGY trial shows that early taxane switch may improve PSA response
rate and that androgen receptor nuclear localization may indicate taxane sensitivity/resistance
was defined as per the Prostate Cancer Working Group 2 guidelines (PCWG2), (10) which is a [greater than or equal to] 50% decline in PSA from baseline maintained for at least three weeks (two consecutive cycles three weeks apart) and measured by the same laboratory, and without evidence of other disease progression documented at time of confirmatory values.
0001) and all secondary endpoints, including confirmed PSA response
rate (54% vs.
Figure 3 illustrates the best PSA response
seen after the initiation of abiraterone.
At week 49, the PSA response
rate for all patients entering the study was 80.
Findings showed anti-tumor activity of sunitinib in combination with docetaxel and prednisone, with a PSA response
occurring in 56 percent of patients with a median time to PSA progression of 42.
9] If AR were upregulated after a prolonged period of androgen deprivation thus making cancer cells more sensitive to anti-androgens, then we might have expected a longer period of PSA response
A benefit we have seen here at CPCC to using Cesium-131 is the strong PSA response
and relatively fast resolution of side effects.
Also, although he lacked a sustained PSA response
to cabazitaxel, the patient reported an increase in well-being and did not want to stop therapy.
Efficacy endpoints include time to clinical disease progression, time to PSA progression and PSA response
, immune response to GVAX immunotherapy, reduction in metabolic bone activity and survival.
5), objective tumor response and PSA response
6] In both trials, PSA response
rates were also statistically significantly higher with docetaxel compared to mitoxantrone.
Patients were monitored for an additional six months following the last injection for adverse events, PSA response
, changes in PSA kinetics, and the induction of prostate cancer-associated antibodies.
The study concluded that "PB with Cesium-131 is effective and well-tolerated; both PSA response
and the acute morbidity profile are very encouraging.
7,8] PSA response
(defined as a 50% decline in baseline PSA) has also been proposed as a predictor of survival following chemotherapy for mHRPC.